1. Rader, R.A., Biopharma market: An inside look, Pharma Manufacturing, 2018. http://www.pharmamanufacturing.com/articles/2018/biopharma-market-an-inside-look. Accessed March 3, 2020.
2. http://lab.express-scripts.com/lab/insights/drug-options/biosimilars-in-the-us-more-approvals-but-not-access. Accessed March 5, 2020.
3. Biosimilars approved in Europe. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed March 9, 2020.
4. Assessment Report for Soliris, International Nonproprietary Name: Eculizumab, Procedure no. EMEA/H/C/000791/II/0050, London: European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), March 21, 2013, EMA/CHMP/126714/2013.
5. Assessment Report for Xolair, International Nonproprietary Name: Omalizumab, Procedure no. EMEA/ H/C/606/II/18, London: European Medicines Agency, June 25, 2009, EMEA/493707/2009.